Iovance Biotherapeutics (IOVA) Competitors $2.30 +0.03 (+1.32%) Closing price 04:00 PM EasternExtended Trading$2.32 +0.02 (+0.65%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IOVA vs. APLS, CRNX, KYMR, TLX, AMRX, RARE, SRRK, XENE, VKTX, and MORShould you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include Apellis Pharmaceuticals (APLS), Crinetics Pharmaceuticals (CRNX), Kymera Therapeutics (KYMR), Telix Pharmaceuticals (TLX), Amneal Pharmaceuticals (AMRX), Ultragenyx Pharmaceutical (RARE), Scholar Rock (SRRK), Xenon Pharmaceuticals (XENE), Viking Therapeutics (VKTX), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry. Iovance Biotherapeutics vs. Its Competitors Apellis Pharmaceuticals Crinetics Pharmaceuticals Kymera Therapeutics Telix Pharmaceuticals Amneal Pharmaceuticals Ultragenyx Pharmaceutical Scholar Rock Xenon Pharmaceuticals Viking Therapeutics MorphoSys Iovance Biotherapeutics (NASDAQ:IOVA) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk. Is IOVA or APLS more profitable? Apellis Pharmaceuticals has a net margin of -30.24% compared to Iovance Biotherapeutics' net margin of -161.44%. Iovance Biotherapeutics' return on equity of -52.87% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Iovance Biotherapeutics-161.44% -52.87% -41.31% Apellis Pharmaceuticals -30.24%-116.09%-26.72% Do analysts prefer IOVA or APLS? Iovance Biotherapeutics presently has a consensus price target of $11.90, indicating a potential upside of 417.39%. Apellis Pharmaceuticals has a consensus price target of $34.12, indicating a potential upside of 43.23%. Given Iovance Biotherapeutics' higher probable upside, research analysts clearly believe Iovance Biotherapeutics is more favorable than Apellis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iovance Biotherapeutics 1 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.36Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.58 Do institutionals & insiders believe in IOVA or APLS? 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 10.3% of Iovance Biotherapeutics shares are owned by insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, IOVA or APLS? Iovance Biotherapeutics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Does the media prefer IOVA or APLS? In the previous week, Apellis Pharmaceuticals had 6 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 11 mentions for Apellis Pharmaceuticals and 5 mentions for Iovance Biotherapeutics. Apellis Pharmaceuticals' average media sentiment score of 1.35 beat Iovance Biotherapeutics' score of 0.97 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apellis Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, IOVA or APLS? Apellis Pharmaceuticals has higher revenue and earnings than Iovance Biotherapeutics. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIovance Biotherapeutics$164.07M5.07-$372.18M-$1.23-1.87Apellis Pharmaceuticals$754.65M3.99-$197.88M-$1.82-13.09 SummaryApellis Pharmaceuticals beats Iovance Biotherapeutics on 10 of the 17 factors compared between the two stocks. Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOVA vs. The Competition Export to ExcelMetricIovance BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$832.26M$3.08B$5.69B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-1.8721.3075.8626.51Price / Sales5.07379.80489.92165.32Price / CashN/A44.4425.8129.89Price / Book0.999.6112.846.32Net Income-$372.18M-$53.28M$3.28B$270.51M7 Day Performance-2.95%0.30%0.20%2.15%1 Month Performance-9.80%4.57%4.59%6.35%1 Year Performance-76.55%9.23%68.31%25.48% Iovance Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOVAIovance Biotherapeutics4.328 of 5 stars$2.30+1.3%$11.90+417.4%-78.0%$832.26M$164.07M-1.87500APLSApellis Pharmaceuticals4.2897 of 5 stars$26.93-4.3%$34.12+26.7%-35.2%$3.40B$781.37M-14.80770Positive NewsCRNXCrinetics Pharmaceuticals3.716 of 5 stars$35.14-1.3%$68.86+96.0%-37.2%$3.31B$1.04M-8.55210KYMRKymera Therapeutics2.3808 of 5 stars$43.26-0.6%$58.76+35.8%+2.6%$3.09B$47.07M-12.47170News CoveragePositive NewsAnalyst ForecastInsider TradeTLXTelix Pharmaceuticals3.6411 of 5 stars$9.05-0.1%$22.33+146.8%N/A$3.06B$637.77M0.00N/AHigh Trading VolumeAMRXAmneal Pharmaceuticals3.2258 of 5 stars$9.73+1.1%$11.60+19.2%+13.6%$3.06B$2.79B973.978,100Positive NewsAnalyst ForecastRAREUltragenyx Pharmaceutical4.2966 of 5 stars$31.51-1.0%$81.50+158.6%-50.6%$3.04B$560.23M-5.701,294SRRKScholar Rock4.4439 of 5 stars$31.52+0.4%$45.75+45.1%+292.9%$3.03B$33.19M-10.83140News CoveragePositive NewsAnalyst ForecastXENEXenon Pharmaceuticals2.3969 of 5 stars$38.19-2.6%$53.30+39.6%-11.9%$2.94B$9.43M-10.76210Positive NewsVKTXViking Therapeutics4.1625 of 5 stars$25.48-5.6%$86.92+241.1%-63.9%$2.86BN/A-16.6520MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730 Related Companies and Tools Related Companies Apellis Pharmaceuticals Competitors Crinetics Pharmaceuticals Competitors Kymera Therapeutics Competitors Telix Pharmaceuticals Competitors Amneal Pharmaceuticals Competitors Ultragenyx Pharmaceutical Competitors Scholar Rock Competitors Xenon Pharmaceuticals Competitors Viking Therapeutics Competitors MorphoSys Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IOVA) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredFree: The Crypto Summit That Could Change Your LifeWall Street’s Crypto Playbook—Revealed at This Free Event If you want to understand what's really happening...Crypto 101 Media | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IOVA Stock Alerts